BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
Covered in this story
Call it yourself
No calls on $ABOS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Acumen Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.